Honigman Advises Eloxx Pharmaceuticals in $66.0 Million Public Offering and Nasdaq Uplisting

Honigman recently advised Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company, in connection with its public offering of 2,975,000 shares of common stock and, in lieu of common stock, pre-funded warrants to purchase up to 3,025,000 shares of common stock, for gross proceeds of approximately $66.0 million, before deducting underwriting discounts and commissions and offering expenses.  In connection with the offering, Eloxx successfully uplisted to trade on Nasdaq.

The offering was priced at $11.00 per share of common stock and $10.99 per pre-funded warrant, which equals the public offering price per share of common stock less the $0.01 per share exercise price of each pre-funded warrant. All securities in the offering were sold by Eloxx.

The Honigman team was led by Corporate Partners N. Danny Shulman and Michael J. Rosenberg, with support from Associates Isaac Pasha, Daniel Altshuller, and Sarah Meinel.